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Abstract
This study investigated the effects of Oligonol intake on cortisol, interleukin (IL)-1β, and IL-6 concentrations in the serum at rest and after physical
exercise loading. Nineteen healthy sedentary male volunteers participated in this study. The physical characteristics of the subjects were: a mean
height of 174.2 ± 2.7 cm, a mean weight of 74.8 ± 3.6 kg and a mean age of 22.8 ± 1.3 years. Each subject received 0.5 L water with Oligonol
(100 mg/day) (n = 10) or a placebo (n = 9) daily for four weeks.  The body composition, the white blood cell (WBC) and differential counts as
well as the serum cortisol, IL-1β, and IL-6 concentrations were measured before and after Oligonol intake. The cortisol concentration and serum
levels of IL-1β and IL-6 after Oligonol intake were significantly decreased compared to before treatment (P< 0.01, respectively). In addition, the
rate of increase of these factors after exercise was decreased compared to the placebo group. There was no change in the WBC and differential
cell counts. These results suggest that oral Oligonol intake for four weeks had a significant effect on inhibition of inflammatory markers in healthy
young men.
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Introduction5)
The plants, vegetables, herbs and spices used in traditional 
medicine have been widely studied for their prophylactic and 
chemopreventive effects on human disease; in addition, they have 
been used for drug discovery and development [1-2]. Oligonol 
is a novel compound produced from the oligomerization of 
polyphenol. It is an optimized phenolic product containing 
catechin-type monomers and oligomers (dimer, trimer, and 
tetramer) of proanthocyanidin that are easily absorbed [3]. 
Oligonol is composed of 50% oligomers whereas a typical 
polyphenol polymer contains less than 10%. Thus, polyphenol 
polymers are not as efficiently bioactive or easily absorbed as 
Oligonol because of their high molecular weight. 
Extracts or other purified preparations of phenolic rich foods 
have antioxidant, antibacterial, anti-inflammatory, antiallergic, 
hepatoprotective, antithrombotic, antiviral, anticarcinogenic, 
vasodilatory, and neuroprotective properties [4-7]. Nagakawa et 
al. [8] examined the effects of proanthocyanidin-rich extracts in 
rats subjected to renal ischemia-reperfusion. Their results 
suggested that Oligonol might play a role in modulating the 
cerebral and renal ischemia associated with oxidative stress. It 
has been shown that Oligonol exhibits significant protection 
against b-amyloid- and high glucose-induced cytotoxicity in rat 
pheochromocytoma PC12 cells and in the porcine proximal 
tubule cell line LLC-PK1, respectively [9,10]. 
In spite of the findings of recent studies on Oligonol, except 
for the study reported by Fujii and colleagues [11], there has 
been no study demonstrating the anti-inflammatory and 
anti-oxidative effects of Oligonol in humans. Thus, the purpose 
of the present study was to examine the effects of Oligonol intake 
for four weeks on cortisol and related cytokines, such as 
interleukin (IL)-6 and IL-1β, in healthy male subjects. 
Exercise-induced stress was evaluated in this study. Exercise 
has acute and chronic effects on the systemic immunity and 
inflammatory response. It causes changes in stress hormones and 
cytokine concentrations. Following prolonged running at high 
intensity, the concentration of serum cortisol has been shown 
to be significantly elevated above control levels for several hours; 
this has been related to many of the cell trafficking changes that 
occur during recovery. Exercise that causes muscle cell injury 
can result in sequential release of pro-inflammatory cytokines, 
such as TNF-α, IL-1β  and IL-6 [12,13]. The inflammatory 
cytokines help regulate the rapid migration of neutrophils, and 
then later monocytes, into the areas of injured muscle cells and 
other metabolically active tissues to initiate repair [14].
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Table 1. Physical characteristics of the subject
Groups Age 
(yrs)
Height 
(cm)
Weight 
(kg) % Fat BMI VO2max 
(ml/kg/min)
Control-G 23.1 ± 1.1 174.6 ± 1.9 72.9 ± 4.7 18.3 ± 4.1 24.3 ± 2.9 48.5 ± 5.2
OL-Sup-G 22.5 ± 1.4 173.8 ± 3.2 76.8 ± 2.3 17.9 ± 4.1 25.1 ± 3.0 51.3 ± 3.3
The  values  are  the  mean ± SD. 
Control-G (placebo-supplemented subjects group, n = 9) and OL-Sup -G (Oligonol- 
supplemented  subjects  group,  n = 10)
Table 2. The composition of the Oligonol
Carbohydrate 93.6-98.6
Protein 1.4-2.2
Lipid 0.0-1.4
Total Polyphenol More than 70
Monomers More than 10
Sodium Not more than 200 mg/100 g
Potassium Not more than 100 mg/100 g
Unit (%)
Subjects and Methods
Subjects
Following approval of the experimental protocol from the 
University of Soonchunhyang Research Committee and obtaining 
written informed consent, normotensive participants were 
enrolled in the study. Nineteen male volunteers, 22.1 years of 
age, participated in this study. The subjects were randomly 
assigned to one of two groups: the Oligonol group (n = 10) 
received Oligonol whereas the control group (n = 9) received a 
placebo similar in appearance.
All of the subjects were informed of the aims, risks and benefits 
of participating in this investigation, both verbally and in writing, 
prior to signing an informed consent document. The study was 
carried out in accordance with the Helsinki Declaration of 1975. 
All subjects refrained from specific medications or diets for the 
period of the study and they restricted alcohol intake and smoking 
before the day of the test. The physical characteristics of the 
subjects are shown in Table 1. There were no significant 
differences in age, height, weight, and % fat and body mass index 
(BMI), VO2max.
The maximum oxygen  consumption and heart rate were 
measured with a pulse sensor on the chest and an expired air 
gas analyzer (COSMED; Quark Pulmonary Function Testing 
Lung Volumes Module 2 ergo, Rome, Italy) during treadmill 
Bruce protocol test. The criteria for determining VO2max were 
that the respiratory exchange ratio was 1.1, VO2max leveled off 
despite increasing workload, and heart rate reached the 
age-predicted maximal value. All of the subjects carried out 60 
min of running at 75% intensity based on the VO2max data.
The oral Oligonol supplement 
Oligonol was supplied by Amino Up Chemical Company 
(Sapporo, Japan), and produced by oligomerization of polyphenols 
rich in lychees. The dose of Oligonol was determined according 
to the study of Fujii and colleagues [11] that demonstrated that 
Oligonol is safe after repeated intake of doses lower than 200 
mg/day. All subjects had 0.5 L water with oral OL intake (100 
mg/2 times/day) for four weeks. The Oligonol was powdered 
and heated to 98~100℃ in reverse osmotic purified water. The 
Oligonol was then filtered and combined in reverse osmotic water 
to maintain the physiological activity of the Oligonol. The 
composition of the Oligonol is shown in the Table 2.
WBC analysis 
Whole peripheral blood was collected from the antecubital vein 
with the subject at rest. The white blood cell count (WBC) and 
differential counts were analyzed using a LH750 Beckman 
Coulter, USA. 
Analysis of cortisol concentration 
Cortisol was determined with the COAT-A-COUNT cortisol/ 
DPC by Radioimmunoassay (RIA, Competitive method), and 
analyzed using the 1470 Wizard (PerkinElmer, Finland) 
Analysis of IL-6 and IL-1β by ELISA
For the analysis of the serum IL-1β (R&D system, USA) and 
IL-6 (R&D systems, San Diego, CA, USA), 100㎕ and 150㎕, 
respectively, of serum was analyzed using kits. The concentrations 
of IL-6 and IL-1β  were measured by an enzyme-linked 
immunosorbent assay (ELISA) reader (Molecular Devices, 
Sunnyvale, CA, USA) at 490 nm. The lower limit of detection 
was 3.13 pg/ml. The values below this limit were assumed to 
be zero for the statistical analysis. The inter- and intra-assay 
coefficients of variance were below 10%. 
Statistical analysis 
Descriptive statistics are expressed as the means ± SD 
(standard deviation) using SPSS/Windows 11.0. Repeated two 
way analysis of variance was used to compare values, and 
contrast method was used to compare values within each group. 
The level of significance was set at P <0 . 0 5 .  
Results
WBC and subtypes 
As shown in Table 3, there were no significant differences 
in the WBC and subtypes between before and after 4 weeks 
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Table 3. Comparison of the WBC and subtypes before and after Oligonol intake
for 4 weeks
Variables
(10
3/L)
Before 4 weeks After
Control-G
(n = 9)
OL-Sup-G
(n = 10)
Control-G
(n = 9)
OL-Sup-G
(n = 10)
WBC 6.45 ± 0.63 5.83 ± 0.84 6.50 ± 0.71 5.95 ± 0.61
Neutrophil 3.21 ± 2.07 2.94 ± 0.79 3.36 ± 1.65 2.73 ± 0.82
Lymphocyte 2.54 ± 2.31 2.17 ± 1.19 2.42 ± 1.93 2.52 ± 1.13
Monocyte 0.52 ± 0.09 0.60 ± 0.08 0.57 ± 0.11 0.62 ± 0.05
Eosinophil 0.12 ± 0.07 0.09 ± 0.05 0.10 ± 0.06 0.05 ± 0.04
Basophil 0.06 ± 0.05 0.03 ± 0.02 0.05 ± 0.04 0.01 ± 0.03
The values are the mean ± SD. 
Control-G (placebo-supplemented subjects group) and OL-Sup-G (Oligonol- 
supplemented subjects group)
Fig. 1. Effect of Oligonol intake and physical loading on the serum cortisol 
concentration level in the Control-G (placebo-supplemented subjects group) and 
OL-Sup-G (Oligonol-supplemented subjects group). Before 4W: before Oligonol 
intake;  Before:  resting  condition,  after  4weeks  Oligonol  intake;  After:  immediately 
after  the  physical  loading  VO2max  75%  for  60  min;  Post  30:  recovery  after  of  30 
min; Post 120: recovery after of 120 min. The values are the mean ± SD. 
### P
< 0.001  and 
# P < 0.05  indicates  a  significant  difference  between  groups.  *** P <
0.001 and * P < 0.05 indicates a significant difference in the each group at Before, 
After,  Post  30  and  Post  120.
Fig. 2. Effect of Oligonol intake and physical loading on serum IL-1β protein 
level in the Control-G (placebo-supplemented subjects group) and OL-Sup-G 
(Oligonol-supplemented subjects group). Before  4W:  before  Oligonol  intake; 
Before: resting condition, after 4weeks Oligonol intake; After: immediately after the 
physical loading VO 2max 75% for 60 min; Post 30: recovery after of 30 min; Post 
120:  recovery  after  of  120  min.  The  values  are  mean ± SD. 
### P < 0.001, 
## P <
0.01 and 
# P <0.05 indicates a significant difference between groups. *** P <0.001 
and  * P < 0.05  indicates a  significant  difference  in  the each group at Before 4W, 
Before,  After,  Post  30  and  Post  120.
Fig. 3. Effect of Oligonol intake and physical loading on serum IL-6 protein level 
in the Control-G (placebo-supplemented subjects group) and OL-Sup-G 
(Oligonol-supplemented subjects group). Before  4W:  before  Oligonol  intake; 
Before: resting condition, after 4weeks Oligonol intake; After: immediately after the 
physical loading VO2max 75% for 60 min; Post 30: recovery after of 30 min; Post 
120: recovery after of 120 min. The values are mean ± SD. 
### P < 0.001 and 
# P
< 0.05 indicates a significant difference between groups. *** P < 0.001 and  * P <
0.05 indicates a significant difference in the each group at Before, After, Post 30 
and  Post  120.
Cortisol, IL-1β and IL-6 concentration 
The serum cortisol concentrations of the groups (all subjects) 
were significantly different in comparisons between the before 
(resting condition) and the after (during the physical loading for 
60 min) values (***P < 0.001, Fig. 1). After Oligonol intake, 
the serum cortisol concentration of the OL-Sup-G was 
significantly reduced compared to the before intake values (Fig. 1).
The IL-1β concentrations of the groups (all subjects) were 
significantly different between the before (resting condition) and 
the after (during the physical loading for 60 min) values (***P
< 0.001, Fig. 2). However, resting IL-1β level of only OL-Sup-G 
was significantly decreased compared to the before Oligonol 
intake (P < 0.05, Fig. 2). 
The IL-6 concentrations of the groups (all subjects) were 
significantly different between the before (resting condition) and 
the after (during the physical loading for 60 min) values (***P
< 0.001, Fig. 3). However, resting IL-6 level of only OL-Sup-G 
was significantly decreased compared to the before Oligonol 
intake (P < 0.05, Fig. 3). 
Discussion
Oligonol is a compound containing catechin-type monomers 
and oligomers derived from the lychee fruit. Several recent 
studies have demonstrated the antioxidative and anti-inflammatory 
potential of Oligonol [1,15-18]. In the present study, the 
anti-inflammatory effects of Oligonol intake were studied. The 
results of this study showed that the serum IL-1β, IL-6, and 
cortisol were significantly reduced as a result of four weeks of 
Oligonol oral supplementation. In addition, acute exercise caused 
a small perturbation of blood inflammatory cytokine levels 
compared with control group. This is the first study to investigate 206 Cortisol and cytokines associated with Oligonol
and demonstrate the anti-inflammatory effects of Oligonol in 
men. 
The circulating numbers and functional capacities of leukocytes 
may demonstrate the ability of immune response and be 
decreased by repeated bouts of intense, prolonged exercise by 
the increased levels of stress hormones during exercise. In our 
results, there was no alteration of WBC and differential counts 
at resting condition despite the decrease of cortisol. Further 
research is needed to identify the effect of Oligonol intake on 
immunity system.
An acute session of physical activity is accompanied by 
responses that are remarkably similar in many respects to those 
induced by infection, sepsis, or trauma [19]; there is a substantial 
increase in the number of circulating leukocytes and inflammatory 
cytokines that are known to influence leukocyte function. 
Hormonal changes also occur in response to exercise, including 
increases in the plasma concentration of several hormones [e.g., 
epinephrine (adrenaline), cortisol, growth hormone, and prolactin] 
that are known to have immunomodulatory effects [20]. Increase 
in the number of circulating leukocytes and inflammatory 
cytokines after exercise is associated with prolonged and high 
intensity endurance exercise. The results of this study showed 
a decrease in the levels of cortisol and cytokines, after Oigonol 
supplementation, which suggests an anti-inflammatory effect of 
Oligonol.
A number of cytokines and hormones change in response to 
exposure to inflammation and stress. It has been well documented 
that proinflammatory cytokines including IL-1β, IL-6 and IFN-γ 
are increased in response to stress [21-22]. Metz et al. [21] 
showed that IL-1β mRNA in the kidney and pituitary of the 
common carp was significantly increased after exposure to acute 
stress for 24-h. In addition, O'Conner et al. [22] reported that 
the IL-1β protein of the hypothalamus, pituitary and spleen of 
rats was significantly increased by an acute severe stress even 
though the IL-6 was unchanged. 
Among the cytokines, IL-1β plays a crucial role in the cytokine 
network and T cell activation during the immune response [23]. 
IL-1β is produced by the activation of phagocytes and other 
antigen-presenting cells under conditions of immune stimulation 
by various microorganisms [24-25]. Therefore, IL-1β has been 
reported to mediate inflammation as well as function as a 
histamine releasing factor [26]; furthermore, it increases with 
exercise [27-28]. IL-6 is classified as an anti-inflammatory 
cytokine [29] and is known to inhibit TNF-α by the stimulation 
of endotoxin; IL-6 plays a crucial role in the host immune 
response, acute protein synthesis and maintenance of homeostasis. 
Communication among the immune-derived signals with the 
hypothalamus-pituitary-adrenal (HPA) axis occurs via IL-1β and 
to a lesser extent with IL-6 and TNF-α. These cytokines have 
been shown to influence neuroendocrine activity in mammals, 
resulting in increased activity of the adrenocorticotropic hormone 
(ACTH) and cortisol during infection, inflammation and stress. 
Among these, IL-1β mediates its effects through the cell surface 
receptor type I (IL-1RI), which forms a receptor complex with 
the recruitment of the IL-1R accessory protein. 
As mentioned above, the effects of Oligonol intake on 
inflammatory cytokine production is not well documented in 
humans. In the present study, the results showed that oral 
Oligonol intake for four weeks had a significant effect on 
inhibition of inflammatory markers and cortisol in healthy young 
men.
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